The market for NSAIDs and Cox-2 inhibitors exceeds $6 billion per year and more than 30 million people worldwide use NSAIDs daily. Due to the recognition of cardiovascular, gastrointestinal and other risks associated with orally administered NSAIDs, and the decline in the use of Cox-2 inhibitors because of safety concerns, the Company believes that there is a significant demand for topical pain management products such as Ketotransdel(TM). If approved by the FDA, Ketotransdel(TM) has the potential to be the first topical NSAID cream product in the United States for acute pain management.
About Transdel Pharmaceuticals, Inc.
Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) is a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically delivered medications. The Company's innovative patented proprietary Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of drugs through the tough skin barrier to reach the target underlying tissues. In the case of Ketotransdel(TM), the Transdel(TM) cream allows the active ingredient ketoprofen to reach the target soft tissue and exert its well-known anti-inflammatory and analgesic effects. The Company is also investigating other drug candidates and treatments for transdermal delivery using the patented Transdel(TM) platform technology for products in pain management and other therapeutic areas.
Safe Harbor Statement
Statements made in this release that are not historical in nature
|SOURCE Transdel Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved